Gilliam recognized subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption that identifies a unique subset of lupus erythematosus. These patients were noted to have prominent photoaggravated skin disease and often had musculoskeletal complaints, but generally did not develop significant systemic disease. SCLE patients were later found to have other distinctive features, including the frequent presence of anti-Ro antibodies, and enrichment for the human histocompatibility antigens (HLA) B8 and DR3. In the 13 years of published reports of SCLE patients following the initial study by Sontheimer et al (Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 115:1409-1415, 1979) a number of additional observations regarding SCLE patients have been made. These have included the recognition that SCLE may be associated with other rheumatic diseases, and that photoactive medications may induce lesions of SCLE. Areas of controversy concerning SCLE include conflicting studies regarding the histopathology of SCLE as compared to discoid lupus erythematosus (DLE), as well as the frequency of detection of anti-Ro antibodies in SCLE patients. Recent interesting studies of SCLE include a description of a unique pattern of immunoglobulin G (IgG) deposition on direct immunofluorescence, which may indicate the binding of anti-Ro antibodies to keratinocytes in vivo. J Invest Dermatol 100:2S-8S, 1993
Two very prominent contributions to dermatology by Gilliam are his classification of cutaneous lesions in patients with lupus erythematosus [1] and particularly his recognition of subacute cutaneous lupus erythematosus (SCLE) as a lupus-specific eruption with distinctive clinical and immunologic features [2, 3] . These clinical observations have enhanced our ability to diagnose and treat lupus patients, and inspired basic research that has advanced our understanding of lupus erythematosus (LE) and general mechanisms of autoimmunity.
In 1989, Sontheimer summarized the worldwide experience with SCLE [4] 10 years after their initial published report describing this disease [3] . He concluded that the initial impressions regarding the clinical, serologic, and genetic homogeneity of SCLE patients were largely supported by the world literature. However, new findings include the association of SCLE with other rheumatic diseases, such as Sjö gren's syndrome and rheumatoid arthritis, and association with medications such as the thiazides. In the past two years, several reports have added further information regarding the clinical, histopathologic, immunofluorescence, serologic, and immunogenetic features of SCLE patients. Additional associated diseases and triggering medications have been identified, and are summarized in this article. New findings regarding the role of ultraviolet radiation in SCLE, and of possible pathogenic mechanisms of SCLE are the subject of separate reviews in this issue.
CLINICAL FINDINGS
As originally described by Sontheimer, Thomas, and Gilliam [3] SCLE consists of an erythematous, nonscarring, papulosquamous eruption occurring in a characteristic photodistribution, with histology consistent with LE. Patients may have predominantly psoriasiform lesions, annular lesions, or a combination of these (Figs 1 and 2). A pityriasiform morphology has also been described. Lesions may result in pigmentary changes and telangiectasia, but characteristically do not result in dermal atrophy or scarring. Examination of the morphology of individual lesions reveals that the scale is less adherent than that typically seen in discoid lupus erythematosus (DLE). Follicular plugging is generally absent. In annular lesions, the central, less active areas may show a grayish hypopigmentation as well as telangiectasia. The border of annular lesions may develop vesiculation or crusting, due to intense basal cell degeneration. With resolution, pigmentary changes, particularly hypopigmentation, may be apparent. Patients with persistent vitiligo-like changes have been described [4] . The distribution of SCLE lesions is primarily in sun-exposed areas, with the upper back and chest, dorsal arms, forearms, and lateral neck the most frequent sites of involvement. On occasion, lesions are seen on the face, scalp, and lower extremities.
Several investigators have compared the disease features of patients with papulosquamous and annular SCLE, but generally have not identified significant differences between these morphologic subtypes of SCLE. Sontheimer et al noted that direct immunofluorescence was positive more frequently in papulosquamous (88%) versus annular lesions (29%) [3] . Patients with annular SCLE have anti-Ro antibodies and the HLA-DR3 phenotype more often than SCLE patients with papulosquamous lesions [5, 6] . A recent study of 11 SCLE patients found that SCLE patients with annular lesion morphology were more likely to be hypocomplementemic, to have circulating immune complexes, and to have positive cutaneous immunofluorescence [7] . They concluded that SCLE patients with annular lesions may be at risk for more severe disease. In contrast to these findings, Sontheimer pointed out that all five of 47 SCLE patients with renal disease in their follow-up study had the papulosquamous variant of SCLE [4] . Thus, one cannot yet determine if lesional morphology assists in the identification of SCLE patients likely to develop severe systemic complications of LE.
Variations in the clinical presentation of SCLE patients include toxic epidermal necrolysis-like changes [8] and exfoliative erythroderma [9] .
Additional LE-specific eruptions have been reported in SCLE patients. In the initial paper by Sontheimer et al, 19% of SCLE patients also had typical DLE lesions, usually localized to the scalp and often preceding the onset of SCLE [3] . In their follow-up study, 15% of SCLE patients had DLE lesions, and 15% had lesions of acute cutaneous lupus erythematosus (ACLE) [10] . Not surprisingly, those SCLE patients with outbreaks of ACLE had more significant systemic disease, including nephritis. Although most studies have reported other LE-specific eruptions in only a small percentage of SCLE patients, a few have reported higher frequencies of DLE (52%) [11] and ACLE (100%) [12] . In the latter study, none of the SCLE patients, all of whom had ACLE, had detectable renal disease at the time of the study. Thus, the importance of ACLE lesions in SCLE patients deserves further study, as clinicians seek clues to identifying SCLE patients at risk for significant systemic illness. LE non-specific skin lesions have also been reported in SCLE patients, generally occurring in only a minority of patients; however, mucous membrane lesions were reported in up to 44% [12] , alopecia in as many as 78% [12] , livedo reticularis in 22% [3] , periungual telangiectasia in up to 51% [13] , vasculitis in 12% [13] , Raynaud's phenomenon in up to 30% [11] , and sclerosis in 7% [3] . An interesting finding in one SCLE patient was gradual replacement of SCLE lesions with plaque-type morphea lesions [14] .
While conducting a study of lupus erythematosus patients, we found that some patients referred as SCLE actually had DLE. This emphasizes the occasional difficulty in distinguishing these two groups clinically. It is particularly important to distinguish DLE from SCLE in studies characterizing the clinical, histologic, serologic, and immunogenetic features of lupus patients. We found two situations where DLE patients were incorrectly diagnosed as SCLE. These included DLE patients with photodistributed lesions (Figs 3 and 4 ) and DLE patients with anti-Ro antibodies. Attention to the morphologic detail of individual lesions, particularly noting the absence of follicular plugging, adherent scale, and evidence of scarring or dermal atrophy in SCLE, should allow for differentiation of DLE from SCLE lesions in nearly all cases. In addition, it was sometimes a challenge to make the correct diagnosis in patients with early DLE lesions where scarring had not yet developed. Preliminary findings from our study suggest that induration may be a particularly helpful feature in discerning early DLE lesions from SCLE lesions [15] .
With regard to systemic disease in SCLE patients, Sontheimer noted in his decade's perspective that their initial impressions regarding the generally good prognosis in SCLE patients were supported by the majority of published reports [4] . Additional reported cases since 1989 have provided further support for this. Drosos et al reported 27 patients with SCLE, 78% of whom met criteria for systemic lupus erythematosus (SLE), with CNS disease found in 15%, but renal disease in none. This particular group of SCLE patients were distinctive in that 85% had exclusively papulosquamous SCLE lesions [11] . None of the 13 patients with SCLE reported by Johansson-Stephansson et al had renal or CNS involvement [16] . Although these reports support the overall favorable course of disease in SCLE patients, it must be emphasized that a few patients will experience significant extracutaneous disease [17] . The importance of determining features that identify SCLE patients at risk for severe systemic disease has been emphasized by Sonth-eimer [4] and continues to be a challenge in clinical research.
HISTOPATHOLOGIC FINDINGS
The histopathologic findings of SCLE were described in the initial article by Sontheimer et al as hydropic degeneration of the epidermal basal cell layer and a mononuclear cell infiltrate around dermal blood vessels and appendages. However, in contrast to DLE, the infiltrate was said to be mononuclear-cell poor, and also follicular dilation, hyperkeratosis, and plugging were much less prominent than that seen in DLE. Thus, they found the histopathologic changes of SCLE to be similar to those of DLE qualitatively, differing only in degree [3] . Other histopathologic findings reported in lesions of SCLE include dermal-epidermal separation due to marked basal cell degeneration [4, 6, 18, 19] , and accumulation of acid muco-polysaccharides [16] .
An issue that has not yet been resolved is the question of whether SCLE can be distinguished from other LE-specific eruptions on the basis of routine histology. A histopathologic study by Bangert et al found that SCLE and DLE lesions could be distinguished histologically in 82% of specimens [20] , They reported that DLE lesions had substantially more hyperkeratosis, basement-membrane thickening, follicular plugging, and superficial and deep inflammatory cell infiltrate, whereas SCLE biopsies had more epidermal atrophy. This paper provided evidence that brought into question the long-held belief that subsets of cutaneous LE could not be distinguished histologically. The findings of Bangert et al [20] were not supported by two subsequent reports. Jerdan et al found that separation of DLE and SCLE by routine histology was not possible in about half of the specimens they reviewed. [21] . They noted that pilosebaceous atrophy was the only distinct significant predictor of DLE versus SCLE. The SCLE patients in this study were unusual in that only seven of 26 had anti-Ro antibodies. Jessop et al also reported preliminary results of a similar comparative histologic study, noting they found no marked differences between the clinical subsets of LE. Interestingly, they also noted that their specific histologic findings in DLE differed markedly from those reported by Jerdan et al [22] . Possible explanations for such disparate results were not offered in this brief report. In contrast to these latter two studies, we reported that DLE and SCLE could be separated reliably in 82% of specimens [23], using criteria similar to those reported by Bangert et al [20] . Prominent hyperkeratosis and a deeper, denser mononuclear cell infiltrate in the dermis were the findings that were characteristic of DLE versus SCLE in this study [23] .
CUTANEOUS IMMUNOFLUORESCENCE FINDINGS
Although the majority of SCLE patients have been reported to have granular deposition of immunoreactants at the dermal-epidermal junction in lesional skin, it has been noted that these deposits are found considerably less often than in lesions of DLE [3] . A minority of SCLE patients have been reported to have immunoreactant 4S DAVID-BAJAR deposition in non-lesional skin [3, 6, 16] . In addition, a unique pattern of immunofluorescence has been reported in SCLE patients. ''Dust-like particles'' of IgG deposition in the epidermis, the subepidermal region, and the dermal cellular infiltrates in 32% of biopsies from SCLE lesions were reported by Nieboer et al [24] . This pattern of staining was not seen in specimens from DLE and SLE patients. These deposits did not correlate with the presence of anti-Ro antibodies in their study. We have reported preliminary findings of a similar paniculate deposition of IgG in the epidermis of SCLE lesions (Fig 5) and have also noted such staining in the non-lesional skin of SCLE patients. All of the SCLE patients in our preliminary study had anti-Ro antibodies [15] . We, too, did not find this pattern of staining in patients with DLE or in SLE patients without cutaneous LE. This interesting immunofluorescent pattern was reported in previous animal studies. Lee et al found similar paniculate epidermal staining in human skin grafted onto immunosuppressed mice, after human anti-Ro antibodies were injected [25] . Such staining was not seen after injection of normal sera, and could be blocked by removal of the anti-Ro antibodies. This suggests that the paniculate epidermal deposition of IgG may indicate the binding of anti-Ro antibodies. Although these findings suggest anti-Ro antibodies may be involved in the pathogenesis of SCLE lesions, their presence in non-lesional skin indicates that additional factors must be important in inducing skin lesions.
SEROLOGIC FINDINGS
The majority of SCLE patients have been reported to have anti-Ro antibodies, in most published series [4] . Reports since Sontheimer's 10-year review further support this finding [7, 11, 16] . When more sensitive techniques, such as the enzyme-linked immunosorbent assay (ELISA), are used, the frequency of anti-Ro antibodies is higher [26] . Table I compares several reported frequencies of anti-Ro antibodies in SCLE patients, using different techniques. Intensive investigations into the nature of the Ro antigen complex are ongoing and are the subject of a separate review in this issue.
IMMUNOGENETICS
Sontheimer and co-workers have reported an increase in the human histocompatibility antigen (HLA) DR3 in SCLE patients, and particularly in those patients with the annular subtype of lesions [5, 27] . Most other groups have found that 50% or more of SCLE patients have the HLA-DR3 phenotype [6, 16, 28] ; however, some have reported lower frequencies [11, 29] . Additional immunogenetic findings include an increased frequency of C4 null alleles [16] and an increase in HLA-DR2 [16, 30] .
ASSOCIATED DISEASES
SCLE lesions have been reported in association with a variety of other systemic diseases -rheumatic and non-rheumatic. These associated diseases have been reported to precede, coincide with, or follow the onset of SCLE.
Rheumatic diseases associated with SCLE include Sjö gren's syndrome [4, 28, 30] and rheumatoid arthritis [31, 32] . The percentage of SCLE patients with associated Sjö gren's syndrome has been variable, with one series reporting only 3% [33] and a recent series with 18% of SCLE patients so affected [11] . Just how commonly one finds Sjö gren's syndrome along with lesions of SCLE overall is unknown. However, such an association would be very important to recognize in the evaluation of patients with SCLE, as significant systemic disease has been reported in these patients [34] . SCLE lesions have also been reported in association with complement abnormalities, including inherited deficiency of the [45] .
In addition, SCLE lesions have been reported with a variety of malignancies, including lung cancer [46] , gastric cancer [47] , breast cancer [48, 49] , and malignant melanoma [50] .
DRUG ASSOCIATIONS
A number of prescribed medications have been associated with the onset or exacerbation of SCLE lesions. The most frequently associated drugs are the thiazides [4, [51] [52] [53] [54] . Other medications associated with SCLE lesions include piroxicam [55] , penicillamine [4] , glyburide [4] , aldactone [56] , chrysotherapy [57] , and griseofulvin [58] . Eruptions suggestive of SCLE were also reported with procainamide [59] and oxyprenolol [60] . These reports emphasize the need for a thorough medication history in the evaluation of patients with SCLE. Many of these patients with medication-induced SCLE had anti-Ro antibodies. An interesting study by Lieu et al [61] suggests that anti-Ro antibodies in patients with drug-induced SCLE recognize different epitopes of the 60-kD Wil-2 Ro protein than do anti-Ro antibodies from patients with SCLE not associated with medications. Further serologic and immunogenetic studies of patients with drug-induced SCLE may advance our understanding of pathogenic mechanisms in this interesting disease.
TREATMENT
Specific treatment of subacute cutaneous lupus erythematosus has been recently reviewed [62] . Education regarding the current understanding of lupus erythematosus in general and SCLE in particular is important in the initial treatment of SCLE patients. Lay literature dealing specifically with SCLE is not readily available; however, the Lupus Foundation distributes brochures that may be pertinent to SCLE patients, including topics such as cutaneous LE, antimalarial drugs, and general information about LE. An explanation of the differences between groups of lupus patients, and reassurance that most SCLE patients thus far have not had significant systemic disease are important concepts to communicate. However, it is also critical that SCLE patients know how to access medical care expeditiously in the event that systemic symptoms develop, and that they are aware of the signs and symptoms of SLE and that serious manifestations of SLE occasionally develop in SCLE patients and require prompt medical attention. In addition, discussion of factors that may aggravate LE, with emphasis on avoiding these, is important. These include natural sunlight as well as artificial ultraviolet radiation in both commercial parlors [63] and physicians offices (PUVA) [64, 65] . Broad-spectrum sunscreens and sun-protective measures should be strongly encouraged as a foundation of the treatment plan. This may need to be reemphasized at each follow-up visit. Patients receiving systemic medications for control of SCLE may believe that these drugs obviate the need for continued sun protection. However, lesions of cutaneous LE have been induced with artificial radiation in patients on systemic therapy [66, 67] . The efficacy of a broad spectrum sunscreen in six patients with SCLE was documented recently [68] . Some SCLE patients have reported that their skin disease worsens with heat [4] ; thus excessive exposure to heat should be avoided if possible.
Medications that can induce or aggravate lesions of SCLE, most commonly the thiazide diuretics, should be avoided. There is experimental evidence that estrogens may enhance expression of the Ro protein on the surface of keratinocytes [69] . Also, estrogen-containing oral contraceptives have been associated with flaring in SLE [70] . To date, there are no clinical studies evaluating the effects of estrogen or progesterone in SCLE patients; however, flaring of SCLE during pregnancy has been noted [71] . Thus, it seems prudent to avoid estrogen-containing medications when possible. Many patients report that stress aggravates their disease, suggesting that attention to general health, including diet, rest, and relaxation, may also be beneficial.
Therapy with moderate to potent topical steroids is often helpful in lesions of SCLE. Close observation for signs of atrophy when potent topical steroids are used is important, as untreated SCLE lesions do not result in significant atrophy. The widespread distribution of SCLE lesions may preclude treatment with potent topical steroids, due to risk of systemic effects as well as excessive expense.
Antimalarial therapy is the systemic therapy of choice when more conservative therapy fails, and has been reported to control 80-90% of SCLE patients [4] . Hydroxychloroquine sulfate and/or quinacrine hydrochloride are the most commonly used antimalarials for cutaneous LE. Response to treatment may require weeks to a few months. Systemic steroids have been used in SCLE patients with severe disease, or to control disease while slower-acting agents, such as antimalarials, are begun. However, it has been emphasized that such treatment should be limited to brief periods to avoid serious side effects.
There are a number of additional systemic treatments that have been reported to be of benefit in SCLE patients. These include dapsone [38, 72, 78] , isotretinoin [74] [75] [76] [77] , etretinate [78, 79] , acitretin [80] , clofazimine [81, 82] , and thalidomide [83] . In addition, azathioprine, cyclophosphamide, methotrexate, plasmapheresis [84] , and pulse methylprednisolone [85] have been used in severe refractory cases of SCLE. A recent report describes short-term benefits using recombinant interferon alpha 2A [86] . Because these latter agents have not been formally evaluated for safety and efficacy in large groups of SCLE patients, careful consideration of the expected benefits and possible risks of such treatment should be given. It should be remembered that SCLE patients most often follow a relatively benign course.
SUMMARY
Gilliam's astute clinical observation that SCLE is a distinctive lupus-specific eruption that identifies a relatively homogeneous subgroup of LE patients has generated over a decade of worldwide interest and study. The majority of published reports support the initial impressions of Gilliam and Sontheimer that SCLE patients typically have prominent cutaneous and musculoskeletal complaints, but generally are spared the serious systemic complications of SLE. Later observations of the unique immunogenetic features of SCLE patients have generated many new areas of research. These include studies of the autoantigen complex to which SCLE patients antibodies are directed, and the possible relationship of these anti-Ro antibodies to the pathogenesis of disease. The significance of Gilliam's contributions to our specialty is evident in the extent of basic research that has evolved from the clinical observations of this exceptional man. 
